C-11-harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies

被引:53
作者
Bergstrom, M
Westerberg, G
Langstrom, B
机构
[1] UNIV UPPSALA,PET CTR,S-75185 UPPSALA,SWEDEN
[2] UNIV UPPSALA,SUBFEMTOMOLE BIORECOGNIT PROJECT,S-75105 UPPSALA,SWEDEN
来源
NUCLEAR MEDICINE AND BIOLOGY | 1997年 / 24卷 / 04期
关键词
positron emission tomography; autoradiography; brain; MAO-A; clorgyline; harmine;
D O I
10.1016/S0969-8051(97)00013-9
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Frozen-section autoradiography in rat brain sections as well as in vivo positron emission tomography (PET) studies in monkey brain were used for the determination of binding characteristics of O-[methyl-C-11]harmine in an attempt to validate this ligand for the assessment of monoamine oxidase A (MAO-A). In frozen sections, the binding of [C-11]harmine showed an apparent KD of the binding of 2 nM. The specific binding was inhibited by nanomolar concentrations of clorgyline, esuprone, brofaromine, and Ro 41-1049. The in vivo kinetic pattern in the monkey brain indicated a significant trapping, which was inhibited by pretreatment with clorgyline, moclobemide, or harmine. Different approaches for a quantitative determination of MAO-A enzyme binding were attempted and demonstrated an IC50 dose of harmine in the range of 0.05-0.1 mg/kg. The studies give strong indications for the validity of [C-11]harmine as an in vivo tracer for the assessment of MAO-A enzyme binding in the brain. (C) 1997 Elsevier Science Inc.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 16 条
[1]  
AMETAMEY SM, 1994, EUR J NUCL MED, V21, P876
[2]   THE INHIBITION OF MONOAMINE-OXIDASE BY BROFAROMINE [J].
ANDERSON, MC ;
WALDMEIER, PC ;
TIPTON, KF .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (12) :1871-1877
[3]   MEASUREMENT OF HUMAN CEREBRAL MONOAMINE-OXIDASE TYPE-B (MAO-B) ACTIVITY WITH POSITRON EMISSION TOMOGRAPHY (PET) - A DOSE RANGING STUDY WITH THE REVERSIBLE INHIBITOR RO-19-6327 [J].
BENCH, CJ ;
PRICE, GW ;
LAMMERTSMA, AA ;
CREMER, JC ;
LUTHRA, SK ;
TURTON, D ;
DOLAN, RJ ;
KETTLER, R ;
DINGEMANSE, J ;
DAPRADA, M ;
BIZIERE, K ;
MCCLELLAND, GR ;
JAMIESON, VL ;
WOOD, ND ;
FRACKOWIAK, RSJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (02) :169-173
[4]  
BERGSTROM M, 1996, UNPUB SYNTHESIS SOME
[5]  
DAPRADA M, 1989, J NEURAL TRANSM-SUPP, V28, P5
[6]  
DUBUQUOY E, 1995, P 11 INT S RAD CHEM, P232
[7]   MONOAMINE OXIDASE-B (MAO-B) INHIBITOR THERAPY IN PARKINSONS-DISEASE - THE DEGREE AND REVERSIBILITY OF HUMAN BRAIN MAO-B INHIBITION BY RO 19 6327 [J].
FOWLER, JS ;
VOLKOW, ND ;
LOGAN, J ;
SCHLYER, DJ ;
MACGREGOR, RR ;
WANG, GJ ;
WOLF, AP ;
PAPPAS, N ;
ALEXOFF, D ;
SHEA, C ;
GATLEY, SJ ;
DORFLINGER, E ;
YOO, K ;
MORAWSKY, L ;
FAZZINI, E .
NEUROLOGY, 1993, 43 (10) :1984-1992
[8]  
GOLLER L, 1995, ONCOL REP, V2, P717
[9]   PERFORMANCE-CHARACTERISTICS OF AN 8-RING WHOLE-BODY PET SCANNER [J].
KOPS, ER ;
HERZOG, H ;
SCHMID, A ;
HOLTE, S ;
FEINENDEGEN, LE .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1990, 14 (03) :437-445
[10]   MEASUREMENT OF CEREBRAL MONOAMINE OXIDASE-B ACTIVITY USING L-[C-11]DEPRENYL AND DYNAMIC POSITRON EMISSION TOMOGRAPHY [J].
LAMMERTSMA, AA ;
BENCH, CJ ;
PRICE, GW ;
CREMER, JE ;
LUTHRA, SK ;
TURTON, D ;
WOOD, ND ;
FRACKOWIAK, RSJ .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1991, 11 (04) :545-556